Methods
The authors conducted a systematic review using a combination of search terms (listed in the online supplementary material of that article), hand searching of online journals and scanning of reference lists of identifi ed citations. Inclusion criteria for studies were: 1) report of data for respiratory syncytial virus (RSV)-infected children with acute lower respiratory tract infection (ALRI) or acute respiratory infection necessitating hospital admission; 2) surveillance within a defi ned population for ≥1 yr; 3) provision of data specifi c to children <5 yrs of age; and 4) report of RSV incidence or mortality for at least the fi rst year of life. Exclusion criteria were: 1) report of data for children with acute upper respiratory infections not necessitating hospital admission; 2) investigation of RSV as a coinfection rather than the primary outcome; 3) use of a case defi nition of infl uenza or infl uenzalike illness; and 4) use of a case defi nition that was not clearly defi ned or consistently applied. No language or publication restrictions were applied for published and unpublished studies. Since data were scarce, authors estimated mortality due to RSV-associated ALRI using three approaches: 1) case fatality ratios and incidence rates; 2) hypoxaemia in RSV-associated severe ALRI admitted to hospital; 3) ALRI mortality during RSV season. The authors chose to defi ne ALRI "as equivalent to clinical pneumonia (acute onset cough or diffi culty in breathing with fast breathing for age)" and "acute cough or diffi culty in breathing with indrawing of the lower chest wall indrawing (with or without fast breathing for age) necessitating hospital admission" were equivalent to severe clinical pneumonia.
Results
897 records were identifi ed, but only 36 had suitable data (26 from published and 10 from unpublished studies); of these, only 30 were fi nally analysed. From this review, it has been
Respiratory syncytial virus: still a global burden for children
The aim of this work was to estimate the global incidence and mortality from acute lower respiratory infection due to respiratory syncytial virus in children <5 yrs of age.
Message
Respiratory syncytial virus is the most common cause of acute lower respiratory infection (ALRI) and an important cause of death from ALRI in children.
estimated that, in the year 2005, at least 33.8 million episodes of new cases of nonsevere RSVassociated ALRI occurred worldwide in children <5 yrs of age, with an incidence in developing countries more than twice that of industrialised countries. By comparison, 13.8 million episodes of pneumococcal pneumonia and 7.9 million episodes of Haemophilus infl uenzae B pneumonia occurred in the same time and in the same age group. Of these 33.8 million episodes, 96% occurred in developing countries (where 90% of the world's population aged <5 yrs reside) and a signifi cant part of RSV-associated morbidity occurs in the fi rst year of life, with incidence in infants that is twice or three times greater than is reported for children <5 yrs of age overall. The estimated global incidence of severe disease in children <5 yrs of age was roughly 3.4 million cases, of which 91% occurred in developing countries. Moreover, it has been also estimated that in the year 2005, 66,000-199,000 children <5 yrs of age died from RSV-associated ALRI, with 99% of these deaths occurring in developing countries. The authors found that estimates of RSV-associated ALRI incidence were highly variable within countries or regions and between regions, and were more likely to be underestimated than to be overestimated, especially in developing countries. RSV diagnostic methods were reported in an extensive table in the original article (table 1) : in most studies, RSV infection was confi rmed with specifi c diagnostic test (e.g. ELISA, virus culture, immunofl uorescence or RT-PCR) while in other studies, these data were not reported or available.
Conclusion
RSV is an important cause of childhood ALRI and a major cause of admission to hospital as a result of severe ALRI. Mortality data suggest that RSV is an important cause of death in childhood from ALRI, and the development of novel prevention and treatment strategies should be accelerated as a priority. 
Original article

Editorial comment
This is an interesting review focusing on the burden of RSV, which remains a major cause of morbidity and mortality from ALRI in infants and children, both in industrialised and developing countries. Even if the median has improved in the last 20 yrs, RSV disease has increased, especially in developing countries: the number of children admitted with RSV diseases from developing countries in 2005 was more than double that estimated in 1986 [1] , and the incidence of RSV-ALRI was twice that of industrialised countries. The current increase and preponderance of the burden of RSV in poor countries should encourage us to fi nd strategies for controlling RSV and to achieve Millennium Development Goal no. 4, which is to reduce by two-thirds the mortality of children <5 yrs of age by 2015 [2] . A RSV study group to supplement a systematic literature review with unpublished data was created by the authors. The novelty of this study is that this study group faced the evaluating studies that adopted one or a combination of three methods of case ascertainment: active community-based, passive hospital-based and clinical-based (further stratifi ed in in-patient and outpatient). Moreover, data from developing countries were included in the study, since the major part of the morbidity and mortality came from these countries. What clearly emerges from this review is that, in examined studies, different approaches to diagnose RSV infections and different defi nitions of severe and nonsevere ALRI are used. These differences created some complexities in comparing data from different countries. Although the authors tried to homogenise the collected data using three different approaches, it is evident that any of these may under-or overestimate RSV infection incidence. For example, in this specifi c case, the authors found that ≤28% of children admitted to hospital were not tested for RSV (for various reasons) and that not all severe case were admitted to hospital: these missing data probably determine a trend towards falsely low reporting estimates and possibly higher mortality in these children.
What could be added to the analysis is a subgroup analysis of children who received the RSV immunoprophylaxis (palivizumab) and should have a lower risk of RSV-associated morbidity and mortality. Future larger studies, including demographic and epidemiological community-based surveillance, are needed to improve our knowledge of RSV, and to reduce morbidity and mortality from this pathogen. F. Saretta and M. Canciani, Italy.
